Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer
This pilot research trial studies circulating tumor deoxyribonucleic acid (DNA) in predicting outcomes in patients with stage IV head and neck cancer or stage III-IV non-small cell lung cancer. Studying circulating tumor DNA from patients with head and neck or lung cancer in the laboratory may help doctors predict how well patients will respond to treatment.
Checked against the public recordLast updated May 15, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Interventions being studied
- Other: Cytology specimen; Other: Laboratory biomarker analysis
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Patients older than 18 years age 2. Diagnosis of advanced HNC (Stage III, IVA, IVB, IVC) or NSCLC (Stage IIA, IIB, IIIA, IIIB, IV) (patients with synchronous advanced HNC and NSCLC are eligible) 3. ECOG performance status score of 0-3 4. Life expectancy of 3 months or longer 5. Patients able to provide a written informed consent prior to study entry Exclusion Criteria: 1. Prior chemotherapy or full course of radiotherapy for their present advanced HNC or NSCLC 2. Patients are excluded if they have a history of any other malignancy from which the patient has been disease-free for less than 2 years, with the exception of adequately treated basal or squamous cell carcinoma of skin 3. Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Thomas Jefferson UniversityPhiladelphia, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 15, 2025. Always confirm current availability with the study team.